Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Fairmount Funds Management LLC (CIK 1802528) reported $1.38B across 12 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: GLTO ($225.7M, 16.30%), DNTH ($212.9M, 15.38%), COGT ($211.8M, 15.30%), SYRE ($202.7M, 14.64%), ORKA ($181.7M, 13.13%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | GLTO | DAMORA THERAPEUTICS INC | $225.7M | 16.30% | 8.7M | New |
| 2 | DNTH | DIANTHUS THERAPEUTICS INC | $212.9M | 15.38% | 2.5M | Added |
| 3 | COGT | COGENT BIOSCIENCES INC | $211.8M | 15.30% | 5.5M | Trimmed |
| 4 | SYRE | SPYRE THERAPEUTICS INC | $202.7M | 14.64% | 4.0M | Hold |
| 5 | ORKA | ORUKA THERAPEUTICS INC | $181.7M | 13.13% | 3.7M | Hold |
| 6 | VRDN | VIRIDIAN THERAPEUTICS INC | $76.6M | 5.53% | 3.9M | Hold |
| 7 | ELVN | ENLIVEN THERAPEUTICS INC | $72.7M | 5.25% | 1.9M | Trimmed |
| 8 | JBIO | JADE BIOSCIENCES INC | $64.0M | 4.62% | 4.6M | Hold |
| 9 | CBIO | CRESCENT BIOPHARMA INC. | $50.5M | 3.65% | 2.7M | Hold |
| 10 | ZBIO | ZENAS BIOPHARMA INC | $46.1M | 3.33% | 2.4M | Added |
| 11 | APGE | APOGEE THERAPEUTICS INC | $25.1M | 1.82% | 298,647 | Trimmed |
| 12 | IKT | INHIBIKASE THERAPEUTICS INC | $14.5M | 1.05% | 8.6M | Hold |
| 13 | NUVL | NUVALENT INC | $0 | 0.00% | 0 | Exited |
| 14 | KNSA | KINIKSA PHARMACEUTICALS INTL | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31